MK-7684A (pembrolizumab/vibostolimab) coformulation
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MK-7684A (pembrolizumab/vibostolimab) coformulation, covering 2025-11-13 to 2025-11-13. Get the full timeline:
Most recent: Clinical Trial Update: Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) [Phase 3]